CE mark given to precision laser system

Article

OptiMedica's Catalys precision laser system has been given the CE mark of approval for corneal incisions.

OptiMedica's Catalys precision laser system has been given the CE mark of approval for corneal incisions.

The system enables the surgeon to conduct precise corneal incisions with accurate orientation, length and depth. Single-plan sideport incisions and self-healing multi-plane cataract incisions can also be performed.

CEO of OptiMedica, Mark J. Forchette, said, "The CE mark approval for corneal incisions is an exciting development that will allow Catalys to bring even more value to the laser cataract procedure. We are thrilled to be able to extend the system’s precision and accuracy benefits to these important surgical steps, as they will further optimize the experience for cataract surgeons and their patients.”

Professor Burkhard Dick, member of OTEurope's Editorial Advisory Board and the first person to use the system, said, "“I believe that Catalys represents the forefront of innovation in laser cataract surgery, and it’s been my pleasure to break new ground by using the system for corneal incisions. It has proven to be a very valuable addition to my practice, and I look forward to continuing to work with OptiMedica to set the new standard in laser cataract surgery.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.